15038 studies
BACKGROUND: Recent trends in use of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonist (RA), versus other glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) re…
Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. However, few licensed and successful pharmacotherapies exist for heterogeneous and complex disorders such as AUD, and these are poorly ut…
BACKGROUND: To compare the effects of switching from dipeptidyl peptidase 4 (DPP-4) inhibitors to oral semaglutide on oxidative stress and glucose variability assessed by continuous glucose monitoring in patients with type 2 diabetes mellitus (T2DM).…
BACKGROUND AND STUDY AIMS: We investigated the effect of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist therapy, on retained gastric contents during endoscopy through a retrospective case-control study. PATIENTS AND METHODS: We performed a re…
Semaglutide is a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) that is approved for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Common adverse drug reactions (ADR) of semaglutide include nausea, vomiting, abdominal pain, const…
Obesity is a global health concern with new medication treatment options. So far, research on how programs with newer anti-obesity medication (AOM) for the moderate- to high-risk population can mitigate the prevalence of obesity and reduce the econom…
We present the case of a 36-year-old man with a history of type 2 diabetes mellitus (T2DM) and prior plantar necrotizing fasciitis, who initially improved on semaglutide but later experienced weight gain and elevated hemoglobin A1C (HbA1c) levels. Af…
BACKGROUND: There is a pressing requirement to formulate innovative approaches for addressing inadequate weight loss or recurrence in individuals following metabolic bariatric surgery (MBS). Glucagon-like peptide- 1 (GLP- 1) analogues such as liraglu…
AIMS: Glycemic control is important for preventing diabetic retinopathy (DR), but rapid improvements could deteriorate the disease. In some, but not all studies, semaglutide is speculated to worsen DR, but the mechanism is unknown. Central retinal th…
Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, are known for their metabolic benefits but may have unrecognized side effects. This study investigates the association between GLP-1 recep…
Fibromyalgia (FM) is a pain disorder characterized by pervasive musculoskeletal pain associated with exhaustion, depression, and irregular sleep patterns. Semaglutide, an innovative glucagon-like peptide-1 (GLP-1) agonist, has shown analgesic effects…
Semaglutide, a novel drug, has shown potential benefits for heart failure with preserved ejection fraction (HFpEF) and obesity in early trials. This study aims to evaluate the efficacy and safety of semaglutide and other glucagon-like peptide-1 (GLP-…
Carnitine plays an essential role in maintaining energy homeostasis and metabolic flexibility. Various medications, such as pivalate-conjugated antibiotics, valproic acid, and anticancer agents, can induce carnitine deficiency, inhibit the utilizatio…
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independe…
The 2024 ESC Guidelines for the management of chronic coronary syndromes expand the concept of CCS (chronic coronary syndrome), adopting a broader vision that includes structural and functional alterations throughout the coronary tree. A significant…
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a well-established agent in managing patients with high cardiovascular risk. Initially, a formulation was introduced for weekly subcutaneous administration that demonstrated good tolerabilit…
Excess or dysfunctional adipose tissue is a key pathophysiological factor in cardiovascular-kidney-metabolic syndrome. However, until very recently, there was no evidence that pharmacological treatments for obesity could significantly impact major ca…